To screen or not to screen for albuminuria? Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of diabetic nephropathy in the Netherlands – A Markov Model

Charles Christian Adarkwah, Silvia Evers & Maren Akkerman
Background: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in the Netherlands as well as in other European countries and the US [ref:1]. In 2010, about 15 000 patients underwent renal-replacement therapy [ref:2]. In the Netherlands, the costs of ESRD treatment[for full text, please go to the a.m. URL]